Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
US-10172873-B2 · Jan 8, 2019 · US
Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
US10849915B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10849915-B2 |
| Application number | US-201816190792-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 14, 2018 |
| Priority date | Aug 6, 2014 |
| Publication date | Dec 1, 2020 |
| Grant date | Dec 1, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
First claim
Opening claim text (preview).
That which is claimed: 1. A method for treating an inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a Prostate Specific Membrane Antigen (PSMA) inhibitor, wherein the PSMA inhibitor is in a neutral form or a salt form. 2. The method of claim 1 , wherein the IBD is selected from the group consisting of Crohn's disease (CD) and ulcerative colitis (UC). 3. The method of claim 1 , wherein the PSMA inhibitor is administered to the subject parenterally.
Assignees
Inventors
Classifications
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Rectum, anus · CPC title
- A61K31/662Primary
Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon · CPC title
Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00) · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10849915B2 cover?
- Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61K31/662. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).